Rachael Brake on TAK-788: Comparative Efficacy #AACR2020 @rachael_brake @TakedaOncology

Rachael Brake @rachael_brake of Takeda @TakedaOncology discusses the therapy designation for mobocertinib (TAK-788) for the treatment of NSCLC patients with EGFR exon 20 insertion mutations